Harrow (HROW) just flipped the switch on HarrowRx, a digital pharmacy platform wired directly into electronic medical records. It gives eye care clinics one hub for prescribing and patient support across its ophthalmic portfolio.
Harrow’s latest move comes after a tough stretch for the share price, with the stock down 42.82% year to date on a share price basis and 27.58% over 90 days. However, the 3 year total shareholder return of 114.91% and 5 year total shareholder return of 148.61% still point to a much stronger longer term record than the recent weakness suggests.
Scan how Harrow compares with 34 healthcare AI stocks that are also wiring their treatments directly into digital workflows and patient-support platforms.
Bulls see HarrowRx turning Harrow into a higher value, workflow-embedded eyecare platform. Bears focus on the recent share price slide and ongoing losses. Which story does the current valuation appear to reflect more?
Most Popular Narrative: 58% Undervalued
Harrow closed at $28.54, while the most followed narrative pegs fair value at $68.38, so the story being told in the models assumes a lot more upside than the tape currently reflects.
The rapidly growing demand for Harrow's portfolio of specialty ophthalmic drugs, particularly VEVYE, IHEEZO, and TRIESENCE, is positioned to accelerate further as aging populations and increased prevalence of chronic ocular diseases expand the baseline patient pool, supporting sustainable long-term revenue growth.
Strategic expansion into new indications and broader patient segments (e.g., TRIESENCE's expected launch into the large ocular inflammation market and BYQLOVI's entry into the post-operative care segment), coupled with rising healthcare access and coverage in the U.S., should increase prescription volumes and elevate top-line performance.
See why 15 investors see Harrow as 58% undervalued.
The narrative leans on a discount rate of 7.11% and arrives at a fair value of $68.38, which sits well above both the $63.00 analyst target in the company data and the current share price. It blends those product and coding catalysts with assumptions about revenue mix, operating leverage and future profitability to justify Harrow trading at that higher level instead of where it is priced today.
Result: Fair Value of $68.38 (UNDERVALUED)
Still, the whole story can change quickly if pricing pressures persist on key drugs, or if new launches and biosimilars stumble in execution.
Find out about the key risks to this Harrow narrative.
Next Steps
Sentiment around Harrow is divided, which is exactly when doing your own homework matters most and speed counts. To examine the potential upside case in detail, take a closer look at the 3 key rewards
Looking for more investment ideas beyond Harrow?
If Harrow has your attention, broaden your watchlist with fresh ideas that match your style, risk tolerance, and preferred income or value profile.
- Spot potential bargains by scanning 35 high quality undervalued stocks that pair solid fundamentals with prices that still look restrained.
- Strengthen your portfolio’s foundation by reviewing the list of solid balance sheet and fundamentals (23 results) so you are not relying on fragile financing.
- Get ahead of the crowd by checking out 19 high quality undiscovered gems before investors start paying closer attention.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com